The role of antiviral and immunoglobulin therapy in the prevention of Epstein–Barr virus infection and post‐transplant lymphoproliferative disease following solid organ transplantation

Transplant Infectious Disease - Tập 3 Số 2 - Trang 97-103 - 2001
Michael Green1,2, Jorgé Reyes2, Steven A. Webber1, David Rowe3
1‡Department of Pediatrics and
2Department of Surgery, University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA
3Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania USA

Tóm tắt

Abstract: The recognition of the importance of Epstein–Barr virus (EBV) infection, including EBV‐associated post‐transplant lymphoproliferative disease (PTLD), has led to a new focus on the prevention of this problem. This paper reviews the scientific rationale behind, and clinical experience with, the use of chemoprophylaxis (using acyclovir or ganciclovir) and immunoprophylaxis (using intravenous immunoglobulin) in the prevention of EBV/PTLD. While some centers have already introduced the use of one or both of these agents as standard prophylaxis against the development of this complication, published data in support of these protocols are currently lacking. Well designed clinical trials are necessary to evaluate the potential role of both antiviral and immunoglobulin agents in the prevention of EBV/PTLD in organ transplant recipients.

Từ khóa


Tài liệu tham khảo

10.1097/00007890-199911270-00015

10.1034/j.1399-3046.1999.00066.x

10.1007/s002810050046

Lin JC, 1984, Prolonged inhibitory effect of 9‐(1,3‐dihydroxy‐2‐propoxymethyl)guanine against replication of Epstein–Barr virus., J Virol, 50, 50, 10.1128/jvi.50.1.50-55.1984

Knowles DM, 1995, Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders., Blood, 85, 552, 10.1182/blood.V85.2.552.552

10.1007/s002810050042

10.1056/NEJM198204153061506

10.1097/00007890-199608150-00012

Riddler SA, 1994, Increased levels of circulating Epstein–Barr virus‐infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid‐organ transplant recipients., Blood, 84, 972, 10.1182/blood.V84.3.972.972

10.1097/00007890-199509270-00005

10.1111/j.1365-2141.1995.tb08904.x

Rowe DT, 1997, Use of quantitative competitive PCR to measure Epstein–Barr virus genome load in peripheral blood of pediatric transplant recipients with lymphoproliferative disorders., J Clin Microbiol, 35, 1612, 10.1128/jcm.35.6.1612-1615.1997

Savoie A, 1994, Direct correlation between the load of Epstein–Barr virus‐infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease., Blood, 83, 2715, 10.1182/blood.V83.9.2715.2715

10.1084/jem.190.4.567

10.1086/315828

Boyle TJ, 1992, Human B‐cell lymphoma in severe combined immunodeficient mice after active infection with Epstein–Barr virus., Surgery, 112, 378

10.1097/00007890-199812270-00006

10.1097/00007890-199709270-00010

Davis CL, 1995, Antiviral prophylaxis and the Epstein–Barr virus‐related post‐transplant lymphoproliferative disorder., Clin Transplant, 9, 53

10.1056/NEJM199104113241509

10.1086/514142

10.1093/clinids/20.5.1346

10.1086/516139

10.1097/00007890-199501150-00024

10.3109/10428199409051672

10.1002/(sici)1097-0215(19970516)71:4<624::aid-ijc19>3.0.co;2-b

Nadal D, 1997, Human immunoglobulin preparations suppress the occurrence of Epstein–Barr virus‐associated lymphoproliferation., Exp Hematol, 25, 223

10.1097/00075200-199909000-00018

10.1097/00007890-200008270-00010

10.1016/S0140-6736(95)91150-2

Thông tin
Thông tin xuất bản

Transplant Infectious Disease

Tập 3 Số 2

97-103

Thông tin tác giả